Botulinum neurotoxin serotype A (BoNT/A) is the most lethal known human poison, exhibiting a potency 1011 times that of cyanide (LD50 ~ 1-5 ng/kg). In addition to this remarkable toxicity, the ease of BoNT/A production and the absence of effective post-exposure interventions have prompted the Centers for Disease Control (CDC) to classify BoNT/A as a biodefense threat of the highest risk to national security. Although immunotherapies exist to protect against BoNT/A toxicity, their effectiveness is lost once the toxin is internalized into neuronal cells (<12 h post-exposure). Compounding this fact, BoNT/A persists intraneuronally on the order of months to >1 year in its toxic form. Small molecules offer the only possibility of inhibiting intraneuronal BoNT/A as these compounds can cross neuronal membranes; however, the development of clinically-relevant therapies has been limited by the short half-lives of these inhibitors, which are only a fraction of the timescale of BoNT/A persistence. In this proposal, we present two pharmacotherapeutic strategies for overcoming BoNT/A persistence in neurons. In the first approach, ubiquitination and proteasomal degradation of BoNT/A can be induced using a bifunctional small molecule known as a proteolysis targeting chimera, or PROTAC. These molecules rely on conjugating a vetted BoNT/A antagonist to an E3 ubiquitin ligase-recruiting ligand. In the cell, these PROTACs tether BoNT/A to the cell?s protein degradation machinery. In the second approach, we will convert known zinc chelating inhibitors of BoNT/A into bifunctional compounds that also covalently engage cysteine 165 of the BoNT/A active site. Covalent modification of this residue will permanently modify the conformation of the active site, inhibiting BoNT/A catalysis and thus, toxicity. To validate these strategies, we will design and synthesize PROTACs (Aim 1) and covalent inhibitors (Aim 2) based on previously reported hydroxamate BoNT/A inhibitors developed by our laboratory. After synthesis, we will extensively evaluate these compounds in in vitro and cellular assays for BoNT/A inhibition. The proposed work will help to achieve our long-term goal of delivering a clinically-relevant pharmacotherapeutic strategy for treating post-exposure BoNT/A intoxication. The objective here is to deliver the first small molecules that effectively overcome BoNT/A persistence in the neuronal compartment. This work is important because we will deliver tools to probe mechanisms of BoNT/A persistence; in addition to, offering novel strategies in BoNT/A therapeutic design. Upon completion of this proposal, the most efficacious and ?drug-like? molecules will be prime for evaluation in relevant in vivo models. This goal is aligned with the mission of the NIAID to support research aimed at developing state-of-the-art treatments for biowarfare agents.

Public Health Relevance

The Centers for Disease Control classifies botulinum neurotoxins (BoNTs) as ?category A? biodefense threats due to their tremendous lethality and a lack of effective countermeasures. Clinical development of small molecule therapeutics for BoNT inhibition has been hindered by the extraordinarily long persistence of the toxin in the body (months to >1 year). In this proposal, we optimize two chemical strategies to irreversibly inactivate BoNT toxins in neurons, laying a foundation for the future development of post-exposure treatments for botulism.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Ranallo, Ryan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code